This is a ready-to-use checklist for a validation or manufacturing science professional, or an entire validation program, moving from one modality into another, small molecule into biologics, biologics into cell or gene therapy, or any other cross-modality move. Its purpose is narrow and specific: confirm explicitly what a control, assay philosophy, or statistical approach from the prior modality actually transfers, rather than letting it carry forward by habit into a modality with different failure modes. Replace every <<FILL: ...>> placeholder with your own specifics. A worked filled specimen follows.
Document control header
| Field | Entry |
|---|---|
| Document title | Cross-Modality Transition Checklist for <<FILL: person, team, or program>> |
| Document number | <<FILL: e.g. CHK-XMOD-002>> |
| Version | <<FILL>> |
| Review date | <<FILL>> |
| Prior modality | <<FILL>> |
| New modality | <<FILL>> |
| Facilitator | <<FILL: e.g. Validation Lead>> |
1. Purpose
This checklist confirms, item by item, whether a control, assay approach, statistical method, or process assumption from the prior modality genuinely transfers to the new one, or needs to be re-derived from the new modality’s own failure modes and data. It exists because the single most common cross-modality mistake is not ignorance of the new modality; it is unexamined confidence that something proven elsewhere still applies.
2. Scope
| Dimension | Decision |
|---|---|
| Person, team, or program in transition | <<FILL>> |
| Prior modality and its representative product type | <<FILL>> |
| New modality and its representative product type | <<FILL>> |
| Out of scope | <<FILL: e.g. facility qualification, covered under its own program>> |
3. Responsibilities
| Role | Responsibility |
|---|---|
| Validation or manufacturing science lead making the transition | Completes this checklist honestly, including items that feel uncomfortable to mark “needs re-derivation” |
| New modality subject matter expert or mentor | Confirms which prior-modality assumptions actually hold and which do not, from direct experience with the new modality’s failure modes |
| Quality Assurance | Reviews items scored “needs re-derivation” against the transition plan, and confirms no item was silently carried forward unexamined |
| Regulatory affairs, where the new modality is subject to a different regulatory framework | Confirms the applicable framework is correctly identified in item 1 |
4. Transition checklist
Score each item Confirmed (verified to transfer, with rationale), Needs Re-derivation (does not transfer as-is), or N/A. A blank score is not a valid state; every item gets an explicit answer.
| # | Item | What “it will just carry over” would wrongly assume | Score | Rationale / evidence |
|---|---|---|---|---|
| 1 | The regulatory framework governing the new modality is named explicitly (for example, 21 CFR 211 and 600-series biologics content, 21 CFR 820.30 device design controls, or cell and gene therapy-specific CBER guidance), not assumed to resemble the prior modality’s framework | The new modality is regulated “basically the same way” as the prior one | <<FILL>> | <<FILL>> |
| 2 | Every control inherited from the prior modality’s quality system has been checked against whether the new modality’s own risk profile actually requires it | A control that made sense in the prior modality is automatically necessary, or automatically sufficient, in the new one | <<FILL>> | <<FILL>> |
| 3 | For each major process step, the specific failure mode the prior modality’s control was built to catch has been named, and checked against whether that failure mode is even physically possible in the new modality | A control transfers because it worked before, without asking what it was actually protecting against | <<FILL>> | <<FILL>> |
| 4 | A failure mode unique to the new modality (chain-of-identity risk in a patient-specific process, particle or formulation instability, device use error, editing specificity) has been identified and given its own named control | The prior modality’s failure-mode list is a complete list | <<FILL>> | <<FILL>> |
| 5 | Every quality attribute carried forward has been checked for whether a single aggregate result still tells the whole story, or whether the new modality’s chemistry or biology requires resolving it into named sub-species or complementary measures | An aggregate percentage that worked as a quality measure in the prior modality still captures what matters in the new one | <<FILL>> | <<FILL>> |
| 6 | Where the new modality’s primary activity or potency assay is inherently higher-variability than the prior modality’s, a triangulation strategy across complementary measures has been considered rather than defaulting to one number | A single assay, once validated, is sufficient because that was true in the prior modality | <<FILL>> | <<FILL>> |
| 7 | The batch-to-patient or batch-to-lot relationship in the new modality is stated explicitly, and deviation and disposition procedures reflect that reality | A failed batch can always be investigated and remade, the way it could in the prior modality | <<FILL>> | <<FILL>> |
| 8 | Any assumption that the new process is simple because the underlying science sounds simple has been tested against an actual characterization exercise | A stepwise chemical or enzymatic process is inherently more predictable than a biological one | <<FILL>> | <<FILL>> |
| 9 | Cold chain, shipping, and distribution have been evaluated as part of the manufacturing process itself, for any modality where a formulation, particle, or biological activity could change in transit | Shipping is a logistics function handled after the real validation work is done | <<FILL>> | <<FILL>> |
| 10 | Sample sizes and acceptance criteria proposed for the new modality trace to that modality’s own process capability and variability data | The prior modality’s typical sample sizes and confidence levels are a safe default | <<FILL>> | <<FILL>> |
| 11 | Every acceptance criterion proposed has been checked against whether it would survive someone else building it from the same data with no knowledge of the answer that was wanted | An acceptance criterion chosen because recent runs happened to clear it is equivalent to one derived from real capability data | <<FILL>> | <<FILL>> |
| 12 | The new modality’s specific vocabulary and characteristic measurements (for example, transduction efficiency and vector copy number, encapsulation efficiency and particle size, coupling efficiency and shortmer species, on-target and off-target editing rate) have been learned well enough to ask an informed question without prompting | Domain vocabulary is a formality that can be picked up passively over time | <<FILL>> | <<FILL>> |
5. Disposition of items needing re-derivation
Any item scored “Needs Re-derivation” is tracked here with an owner and a plan; it is not carried silently into the new program.
| Item # | Gap | Re-derivation plan | Owner | Target date |
|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
6. Overall disposition
| Field | Entry |
|---|---|
| Total items confirmed | <<FILL>> of 12 |
| Items needing re-derivation, with an open plan | <<FILL>> |
| Items needing re-derivation, with no plan (blocks sign-off) | <<FILL>> |
| Facilitator recommendation | Proceed with the transition / Hold pending re-derivation of item(s) <<FILL>> |
7. References
See the paired article, one validation mindset, six modalities, for the reasoning behind each item. Cite the specific regulatory framework identified in item 1 by its own current, verified reference; this checklist deliberately does not name one framework, since the item’s purpose is to force that identification for the modality actually in scope.
8. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
9. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Facilitator | <<FILL>> | ||
| Reviewer (Quality Assurance) | <<FILL>> |
Filled specimen
Extract for a validation lead moving from Acme Therapeutics’ monoclonal antibody drug substance program onto Acme Therapeutics’ new autologous CAR-T cell therapy program. Company and product are illustrative.
| # | Item | Score | Rationale / evidence |
|---|---|---|---|
| 1 | Regulatory framework named | Confirmed | Identified 21 CFR 600-series biologics content plus CBER’s cell and gene therapy-specific CMC guidance as the applicable framework, distinct from the prior program’s more conventional BLA content |
| 3 | Failure mode named per control | Needs Re-derivation | The prior program’s in-process bioburden control assumed a large-volume bioreactor with redundant sampling; the new process runs a single small-volume patient lot with no redundant sample to fall back on if a result is questioned |
| 5 | Aggregate result vs. sub-species | N/A | Not applicable to this specific transition; the cell therapy process does not carry an analogous purity-ladder attribute |
| 6 | Potency triangulation | Needs Re-derivation | Prior program relied on a single validated cell-based bioassay; new program’s potency strategy is still being scoped and needs a triangulation plan before PPQ, given cell-based assay variability |
| 7 | Batch-to-patient relationship stated | Confirmed | Deviation procedure rewritten to remove language assuming a failed batch can be remade from held reserve material; new procedure states explicitly that an autologous batch has no such reserve |
| 9 | Cold chain as process | Confirmed | Apheresis-to-manufacturing and product-to-clinic shipping both added to the process map as validated steps, not logistics handoffs |
Disposition: item 3 and item 6 were scored Needs Re-derivation. Item 3’s re-derivation plan, owned by the incoming validation lead with a target date ahead of process characterization completion, is to define a single-lot-appropriate bioburden control strategy with the analytical SME. Item 6’s plan, owned jointly with the potency assay SME, is to scope a triangulated potency strategy (a functional bioassay alongside a transduction or expression readout) before PPQ protocol approval. Facilitator recommendation: proceed with the transition, with both open items tracked to closure before PPQ readiness review.
Common findings this checklist prevents
- A control carried forward from a prior modality with no one asking whether the new modality’s failure modes actually match the ones it was built to catch.
- A batch disposition procedure that still assumes a next lot exists, discovered only after the first real patient-scale batch fails.
- A single potency number trusted in a new, higher-variability modality simply because a single number was sufficient in the prior one.
- Cold chain or shipping left unvalidated because it was treated as a logistics handoff rather than part of the process, in a modality where transit conditions can change the product.
How to adapt this checklist
- Set the prior and new modality explicitly in the header; a vague description of either makes every item harder to score honestly.
- Bring in a genuine subject matter expert in the new modality to challenge each “Confirmed” score before it is accepted; a transitioning individual’s own optimism is the least reliable check on this checklist.
- Route every “Needs Re-derivation” item through section 5 with a real owner and date, not a general intention to “keep an eye on it.”
- Revisit this checklist again after the first real characterization or engineering run in the new modality; several items are easier to score honestly with real data in hand than during the transition planning itself.